Bempedoic Acid Pregnancy Surveillance Program

NCT05103254 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2024-05-17

No results posted yet for this study

Summary

Bempedoic acid pregnancy surveillance program

Conditions

  • Pregnancy
  • Hyperlipidemias

Interventions

DRUG

Bempedoic Acid

Bempedoic Acid 180 MG

DRUG

Bempedoic Acid / Ezetimibe

Bempedoic Acid 180 MG / Ezetimibe 10 MG

Sponsors & Collaborators

  • Esperion Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Christine Broestl, MS · Esperion Therapuetics

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2032-05-31
Completion
2032-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05103254 on ClinicalTrials.gov